Compare LGL & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGL | NRSN |
|---|---|---|
| Founded | 1917 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.6M | 30.5M |
| IPO Year | N/A | 2021 |
| Metric | LGL | NRSN |
|---|---|---|
| Price | $6.91 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 21.1K | ★ 231.6K |
| Earning Date | 11-13-2025 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 149.85 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $4,107,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.45 | $0.68 |
| 52 Week High | $9.74 | $2.60 |
| Indicator | LGL | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 58.92 | 56.84 |
| Support Level | $6.54 | $0.95 |
| Resistance Level | $7.26 | $1.06 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 58.34 | 77.15 |
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.